Chris Gilmore has been named Aprecia’s CEO. Gilmore previously served as VP, strategic business ventures at Prasco Laboratories. Aprecia is the world’s first and only manufacturer of FDA-approved pharmaceutical products using three dimensional printing (3DP).
Lloyd Sanders has become CEO and Richard J. Wenstrup, M.D. is now chief medical officer of Epic Sciences Inc. Sanders was president of the oncology segment of the molecular diagnostics company Myriad Genetics. Dr. Wenstrup was previously chief medical officer for Oxford Immunotec Inc. Epic Sciences is developing novel diagnostics to personalize and advance the treatment and management of cancer.
Melody Harris has been appointed president of SomaLogic. Harris joined SomaLogic in April 2018 as chief legal officer. Harris initially joined Qualcomm Life with the acquisition of HealthyCircles (a technology spin-out from Microsoft HealthVault), where she served as general counsel. SomaLogic delivers meaningful and actionable health-management insights that empower individuals worldwide to continuously optimize their personal health and wellness throughout their lives.
David B. Fleishman, MBA, is now a principal of BBK Worldwide. Fleishman joined BBK 10 years ago. BBK Worldwide is committed to enhancing the clinical trial patient journey through a combination of services and technology-driven solutions that educate consumers, engage participants, unburden sites, and support sponsors.
Jack Crowley joined cancer genomics company Personal Genome Diagnostics Inc. as chief financial officer. Crowley has extensive experience overseeing finance organizations for Fortune 500 and private equity-backed companies, most recently serving as chief financial officer at Lantheus Medical Imaging Inc.
PatientPoint named Bill Jennings as chief digital officer, as he oversees all of the company’s proximity marketing and programmatic video solutions. Jennings brings more than 20 years of digital media and video experience to PatientPoint, which is a leader in patient engagement solutions.
SkinBioTherapeutics tapped Stuart Ashman as an executive director, effective from April 18th. Ashman succeeds Professor Cath O’Neill as CEO after a period of transition. O’Neill continues to drive the science and ongoing commercial discussions she has initiated for SkinBioTherapeutics, a life science company focused on skin health.
JDRF, a global organization funding type 1 diabetes research, appointed Aaron J. Kowalski, Ph.D., as the nonprofit’s president and CEO. A 15-year veteran of JDRF and the first individual living with T1D to lead the research organization, Dr. Kowalski has a strong record of spearheading impactful strategic initiatives and forging new partnerships from his previous role as JDRF’s first chief mission officer.
Matthew West has become chief talent officer of Marathon Strategies. Prior to joining Marathon, he worked as a director at Advice Personnel, a NYC-based recruiting firm. Marathon Strategies is an independent, full-service communications and research firm.
John R. Mosack is now VP of manufacturing for Paragon Bioservices’ commercial-scale gene therapy facility in Baltimore. Additionally, Paragon has appointed Adam Sachs as VP of program management and strategic client alliance to further support its customers throughout the life cycle of their product. Mosack joins Paragon with more than 25 years of GMP operations management, validation and compliance experience in small- and large-scale clinical and commercial biologics manufacturing operations. Most recently, he was the site head for Lonza’s Bioscience and Cell Therapy operations at the Walkersville, Md., production facility. Sachs was at AstraZeneca/MedImmune where he served as senior director in both business development and alliance management. In addition to the two new leadership positions, Paragon recently promoted Deborah Wild to chief quality and regulatory affairs officer. Wild had been a consultant and VP of quality systems at Polynoma and VP of manufacturing and supply chain at Victory Pharma. Paragon Bioservices is a private equity-backed biologics contract development and manufacturing organization, which recently entered into a definitive agreement with Catalent Inc.
Sridhar Krishnan has been appointed senior VP, global operations, of Frontage Laboratories Inc. In his role, Krishnan is responsible for integrating business units and provide operational excellence leadership across the Frontage organization. Krishnan was at Catalent Pharma Solutions as VP, global procurement and business analytics. Frontage is a contract research organization.
Clarivate Analytics has appointed Sarah Hardison, Ph.D., and Garth Ringheim, Ph.D., to the company’s Life Sciences Strategy & Thought Leadership team. Prior to joining Clarivate, Hardison held product and portfolio management roles in life sciences reagents companies such as Abcam and Horizon Discovery, where she established a pipeline of research-use antibodies and developed a suite of preclinical screening services for immune-oncology biologics. Dr. Ringheim brings nearly 30 years of pharmaceutical and biotechnology industry experience to Clarivate, with deep expertise in bringing drug candidates from discovery research and development through to clinical trials and regulatory approvals at Sanofi and Celgene. Clarivate Analytics is a global leader in providing trusted insights and analytics to accelerate the pace of innovation.